Welcome!

News Feed Item

Global Survey of Cardiologists Highlights Complexity of Managing Non-Valvular Atrial Fibrillation and Reinforces Need for Individualized Approach to Patient Care

- Findings show risk of bleeding, along with overall efficacy(1), consistently ranked among top considerations for cardiologists when choosing a treatment to reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF)

BARCELONA, Spain, Aug. 31, 2014 /PRNewswire/ -- Daiichi Sankyo and the Heart Rhythm Society today announced results from a global survey, which polled cardiologists from around the world and revealed that a majority (58%) of cardiologists agree that there is no such thing as a "typical" non-valvular atrial fibrillation (NVAF) patient.1 Additionally, 88% of cardiologists agree that NVAF patients are diverse, and therefore it is important to focus on individual co-morbidities and patient characteristics to provide appropriate disease management.1 On average, according to the survey, NVAF patients have about three co-morbid conditions.1

The global survey, conducted online by Harris Poll in July and August 2014 on behalf of the Heart Rhythm Society and Daiichi Sankyo, involved 1,100 cardiologists from seven countries, including Brazil, France, Germany, Japan, Spain, United Kingdom (UK) and United States (U.S.).

The survey examined the management of NVAF and, according to the global survey results, patient risk of bleeding, history of hemorrhagic stroke and patient compliance are the top three very important or important factors cardiologists consider when managing anticoagulation therapy for stroke prevention in patients with NVAF (from a given list of 23 factors).1 The survey also found that, when managing anticoagulation therapy for stroke prevention in patients with NVAF, the most important factor in choosing a treatment for stroke prevention is the overall efficacy profile of the medication.1

Among cardiologists who have at least some patients not receiving OAC therapy, on average, approximately one out of every three of these patients have an appropriate stroke risk level to warrant OAC therapy based on current treatment guidelines.1 Globally, patient refusal, high risk of bleeding and contraindications were the top three reasons why some patients with NVAF do not receive treatment with an OAC for stroke prevention.1

"A revealing finding from this global survey is that a significant portion of NVAF patients who warrant anticoagulation are not receiving OAC therapy," said Hugh Calkins, MD, FHRS and Immediate Past President, Heart Rhythm Society. "Another particularly important finding was that across all countries surveyed, nearly all cardiologists reported that NVAF patients are likely to have experienced a delay in diagnosis."

The survey reported that nearly all cardiologists (98%) believe NVAF patients may experience a delay in diagnosis, primarily because they are asymptomatic (86%), but also due to low awareness among primary care physicians, general practitioners (40%) and the general public (36%).1

The survey also explored unmet needs in the management of NVAF, including coordinated care and the role of the caregiver. Coordinated care in other disease areas has been found to improve patient outcomes,2 and according to the survey, 84% of cardiologists believe that coordinated care among healthcare professionals is important for the management of NVAF. However, only one in three (33%) believe that coordinated care for the management of NVAF is currently adequate in their respective countries.1

As part of a coordinated care approach to treating NVAF, the role of the caregiver was also seen as important, with 75% of cardiologists agreeing there is an opportunity for caregivers to play a more prominent role in helping patients manage NVAF.1 On average, cardiologists reported that just under 50% of their NVAF patients have a caregiver.1 Seventy-three percent of cardiologists who have patients both with and without a caregiver believe that their NVAF patients with a caregiver are better able to manage their condition than their NVAF patients without a caregiver. In addition, 84% of cardiologists agree that caregivers should help patients communicate with all the healthcare professionals they see/visit.1  

"Daiichi Sankyo partnered with the Heart Rhythm Society on this global survey to further understand the perspectives of cardiologists regarding NVAF patients and the complexities surrounding management of this disease. These results further underscore that a 'one-size-fits-all' approach is not the ideal way to manage NVAF," said Wolfhard Erdlenbruch, Executive Director Medical Affairs, Daiichi Sankyo. "The survey findings indicate that more work needs to be done to support patients with NVAF and Daiichi Sankyo is proud to be committed to advancing awareness, understanding and research about NVAF in order to support the diverse needs of this patient population."

About the Survey
The global survey of cardiologists was conducted by Harris Poll on behalf of Daiichi Sankyo and the Heart Rhythm Society among a total of 1,100 licenced cardiologists from around the globe as follows: U.S. (n=160), Japan (n=161), UK (n=157), Germany (n=156), France (n=159), Brazil (n=153) and Spain (n=154). All data collection was conducted online between July 15 and August 7, 2014. The survey was designed to help facilitate and raise awareness about the diversity of the global AF patient population and the challenges in appropriately managing these patients, physician perceptions of unmet needs of AF and a better understanding of specific challenges associated with AF, including delayed diagnosis, coordination of patient care and co-morbidities. To qualify for the survey, cardiologists were required to have seen a minimum of five patients per month with NVAF. Within the U.S., data were weighted where necessary by age, region and years in practice by gender to bring them in line with their actual proportions in the population. Within Spain, Germany, UK, Japan and Brazil, data were weighted by age and gender to bring them in line with their actual proportions in the population. For the global 7-country total, an additional post-weight was applied to adjust for the relative size of each country's population within the total population across all countries surveyed.

About Atrial Fibrillation (AF)
Atrial fibrillation (AF) is a condition in which the heartbeat is rapid and irregular, and can potentially lead to a stroke.3 Atrial fibrillation is a common condition, affecting approximately 2.3-3.4% of people in developed nations.4 Atrial fibrillation affects approximately 6 million people in the EU,5 approximately 6.1 million people in the U.S.,6 approximately 1.5 million people in Brazil7 and more than 800,000 people in Japan.8 Stroke due to all causes is the second most common cause of death worldwide, responsible for approximately 6.2 million deaths each year.9 Compared to those without AF, people with the arrhythmia have a 3-5 times higher risk of stroke.4 Strokes due to AF are nearly twice as likely to be fatal than strokes in patients without AF at 30 days10 and have poorer prognosis than non-AF related strokes, with a 50% increased risk of remaining disabled at three months.11 For more information about AF, symptoms, risk factors, prevention and treatment, please visit the Heart Rhythm Society's www.myAFib.org.

About Heart Rhythm Society
The Heart Rhythm Society is the international leader in science, education and advocacy for cardiac arrhythmia professionals and patients, and the primary information resource on heart rhythm disorders. Its mission is to improve the care of patients by promoting research, education and optimal health care policies and standards. Incorporated in 1979 and based in Washington, DC, it has a membership of more than 5,800 heart rhythm professionals in more than 72 countries around the world.

About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, dyslipidemia and bacterial infections used by patients around the world, the Group has also launched treatments for thrombotic disorders and is building new product franchises. Furthermore, Daiichi Sankyo research and development is focused on bringing forth novel therapies in oncology and cardiovascular-metabolic diseases, including biologics. The Daiichi Sankyo Group has created a "Hybrid Business Model" to respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit: www.daiichisankyo.com.

Contact



Kennesha Baldwin


Michaela Paudler-Debus, PhD

The Heart Rhythm Society


Daiichi Sankyo

[email protected]


[email protected]

+ 1 202 464 3476 (office)


+49 89 7808 685 (office)

+ 1 202 590 6757 (mobile)


+49 176 11780966 (mobile)




Alyssa Dargento


Daria Munsel

Daiichi Sankyo, Inc.


Daiichi Sankyo Europe GmbH

[email protected]


+49 (89) 7808728 (office)

+1 973 944 2913 (office)


+ 49 176 11780826 (mobile)

+1 973 727 1604 (mobile)



References

1 AFIB Global Survey of Cardiologists, Harris Poll on behalf of Daiichi Sankyo and the Heart Rhythm Society, July 15Aug 07, 2014 (Data on file)

2 Engelhardt, J et al. Effectiveness of Care Coordination and Health Counseling in Advanced Illness. American J of Managed Care 2009; 15:817-825.

3 Patient.co.uk. Atrial fibrillation. Available at: http://www.patient.co.uk/pdf/4198.pdf. Updated 2012. Last accessed August 2014.

4 Ball, J et al. Atrial fibrillation: Profile and burden of an evolving epidemic in the 21st century. Int J Card 2013; 167:1807-1824.

5 Camm, A et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Euro Heart J. 2010;31:2369-429.

6 Go, A S et al. Heart Disease and Stroke Statistics -- 2013 Update: A Report From the American Heart Association. Circulation. 2013; 127:6-245.

7 Zimerman, Ll. et al. Sociedade Brasileira de Cardiologia [Brazillian guidelines on atrial fibrilation]. Arq Bras Cardiol. 2009;92:1-39.

8 Inoue, H et al. Prevalence of atrial fibrillation in the general population of Japan: An analysis based on periodic health examination. Int J Cardiol 2009 Oct 2;137(2):102-7.

9 World Health Organization. The top 10 causes of death. July 2013. Available at: who.int/mediacentre/factsheets/fs310/en/. Last accessed August 2014.

10 Lin H et al. Stroke severity in atrial fibrillation. Stroke 1996; 27:1760-1764

11 Lamassa A et al. Characteristics, Outcome, and Care of Stroke Associated With Atrial Fibrillation in Europe. Stroke 2001; 32:392-398.

SOURCE Daiichi Sankyo

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Datera, that offers a radically new data management architecture, has been named "Exhibitor" of SYS-CON's 21st International Cloud Expo ®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Datera is transforming the traditional datacenter model through modern cloud simplicity. The technology industry is at another major inflection point. The rise of mobile, the Internet of Things, data storage and Big...
SYS-CON Events announced today that Akvelon will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Akvelon is a business and technology consulting firm that specializes in applying cutting-edge technology to problems in fields as diverse as mobile technology, sports technology, finance, and healthcare.
WebRTC is great technology to build your own communication tools. It will be even more exciting experience it with advanced devices, such as a 360 Camera, 360 microphone, and a depth sensor camera. In his session at @ThingsExpo, Masashi Ganeko, a manager at INFOCOM Corporation, will introduce two experimental projects from his team and what they learned from them. "Shotoku Tamago" uses the robot audition software HARK to track speakers in 360 video of a remote party. "Virtual Teleport" uses a...
SYS-CON Events announced today that Datera will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Datera offers a radically new approach to data management, where innovative software makes data infrastructure invisible, elastic and able to perform at the highest level. It eliminates hardware lock-in and gives IT organizations the choice to source x86 server nodes, with business model option...
When shopping for a new data processing platform for IoT solutions, many development teams want to be able to test-drive options before making a choice. Yet when evaluating an IoT solution, it’s simply not feasible to do so at scale with physical devices. Building a sensor simulator is the next best choice; however, generating a realistic simulation at very high TPS with ease of configurability is a formidable challenge. When dealing with multiple application or transport protocols, you would be...
With 10 simultaneous tracks, keynotes, general sessions and targeted breakout classes, Cloud Expo and @ThingsExpo are two of the most important technology events of the year. Since its launch over eight years ago, Cloud Expo and @ThingsExpo have presented a rock star faculty as well as showcased hundreds of sponsors and exhibitors! In this blog post, I provide 7 tips on how, as part of our world-class faculty, you can deliver one of the most popular sessions at our events. But before reading the...
In his session at 21st Cloud Expo, Carl J. Levine, Senior Technical Evangelist for NS1, will objectively discuss how DNS is used to solve Digital Transformation challenges in large SaaS applications, CDNs, AdTech platforms, and other demanding use cases. Carl J. Levine is the Senior Technical Evangelist for NS1. A veteran of the Internet Infrastructure space, he has over a decade of experience with startups, networking protocols and Internet infrastructure, combined with the unique ability to it...
Internet of @ThingsExpo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devic...
Historically, some banking activities such as trading have been relying heavily on analytics and cutting edge algorithmic tools. The coming of age of powerful data analytics solutions combined with the development of intelligent algorithms have created new opportunities for financial institutions. In his session at 20th Cloud Expo, Sebastien Meunier, Head of Digital for North America at Chappuis Halder & Co., discussed how these tools can be leveraged to develop a lasting competitive advantage ...
SYS-CON Events announced today that CA Technologies has been named "Platinum Sponsor" of SYS-CON's 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business - from apparel to energy - is being rewritten by software. From planning to development to management to security, CA creates software that fuels transformation for companies in the applic...
SYS-CON Events announced today that Elastifile will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Elastifile Cloud File System (ECFS) is software-defined data infrastructure designed for seamless and efficient management of dynamic workloads across heterogeneous environments. Elastifile provides the architecture needed to optimize your hybrid cloud environment, by facilitating efficient...
“Why didn’t testing catch this” must become “How did this make it to testing?” Traditional quality teams are the crutch and excuse keeping organizations from making the necessary investment in people, process, and technology to accelerate test automation. Just like societies that did not build waterways because the labor to keep carrying the water was so cheap, we have created disincentives to automate. In her session at @DevOpsSummit at 20th Cloud Expo, Anne Hungate, President of Daring System...
As DevOps methodologies expand their reach across the enterprise, organizations face the daunting challenge of adapting related cloud strategies to ensure optimal alignment, from managing complexity to ensuring proper governance. How can culture, automation, legacy apps and even budget be reexamined to enable this ongoing shift within the modern software factory?
Most companies are adopting or evaluating container technology - Docker in particular - to speed up application deployment, drive down cost, ease management and make application delivery more flexible overall. As with most new architectures, this dream takes a lot of work to become a reality. Even when you do get your application componentized enough and packaged properly, there are still challenges for DevOps teams to making the shift to continuous delivery and achieving that reduction in cost ...
"Cloud computing is certainly changing how people consume storage, how they use it, and what they use it for. It's also making people rethink how they architect their environment," stated Brad Winett, Senior Technologist for DDN Storage, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.